Decompensated heart failure

Sandrigo Mangini, Philippe Vieira Pires, Fabiana Goulart Marcondes Braga, Fernando Bacal, Sandrigo Mangini, Philippe Vieira Pires, Fabiana Goulart Marcondes Braga, Fernando Bacal

Abstract

Heart failure is a disease with high incidence and prevalence in the population. The costs with hospitalization for decompensated heart failure reach approximately 60% of the total cost with heart failure treatment, and mortality during hospitalization varies according to the studied population, and could achieve values of 10%. In patients with decompensated heart failure, history and physical examination are of great value for the diagnosis of the syndrome, and also can help the physician to identify the beginning of symptoms, and give information about etiology, causes and prognosis of the disease. The initial objective of decompensated heart failure treatment is the hemodynamic and symptomatic improvement preservation and/or improvement of renal function, prevention of myocardial damage, modulation of the neurohormonal and/or inflammatory activation and control of comorbidities that can cause or contribute to progression of the syndrome. According to the clinical-hemodynamic profile, it is possible to establish a rational for the treatment of decompensated heart failure, individualizing the proceedings to be held, leading to reduction in the period of hospitalization and consequently reducing overall mortality.

Figures

Figure 1. Clinical assessment of decompensated heart…
Figure 1. Clinical assessment of decompensated heart failure
Figure 2. Diagnostic assessment of decompensated heart…
Figure 2. Diagnostic assessment of decompensated heart failure
Figure 3. Treatment algorithm of decompensated heart…
Figure 3. Treatment algorithm of decompensated heart failure

References

    1. Bocchi EA, Vilas-Boas F, Perrone S, Caamaño AG, Clausell N, Moreira Mda C, Thierer J, Grancelli HO, Serrano CV, Junior, Albuquerque D, Almeida D, Bacal F, Moreira LF, Mendonza A, Magaña A, Tejeda A, Chafes D, Gomez E, Bogantes E, Azeka E, Mesquita ET, Reis FJ, Mora H, Vilacorta H, Sanches J, Souza Dd, Neto, Vuksovic JL, Moreno JP, Aspe y Rosas J, Moura LZ, Campos LA, Rohde LE, Javier MP, Garrido Garduño M, Tavares M, Castro Gálvez P, Spinoza R, Castro de Miranda R, Rocha RM, Paganini R, Castano Guerra R, Rassi S, Lagudis S, Bordignon S, Navarette S, Fernandes W, Pereira Barretto AC, Issa V, Guimarães JI. Grupo de Estudos de Insuficiência Cardíaca; Brazilian Society of Cardiology; Argentine Federation of Cardiology; Argentine Society of Cardiology; Chilean Society of Cardiology; Costa Rican Association of Cardiology; Colombian Society of Cardiology; Equatorian Society of Cardiology; Guatemalan Association of Cardiology; Peruvian Society of Cardiology; Uruguayan Society of Cardiology; Venezuelan Society of Cardiology; Mexican Society of Cardiology; Mexican Society of Heart Failure; Interamerican Society of Heart Failure. I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure. Arq Bras Cardiol. 2005;85(Suppl 3):49–94. 1-48.
    1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–e479.
    1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–869. Erratum in: Eur J Heart Fail. 2013;15(3):361-2.
    1. Brasil . Datasus: morbidade hospitalar do SUS por local de internação — Brasil [Internet] Brasília (DF): Ministério da Saúde; c2008. [citado 2013 Set 18]. Ministério da Saúde. Disponível em: .
    1. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L. International Working Group on Acute Heart Failure Syndromes. International working group on acute heart failure syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958–3968.
    1. Adams KF, Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design and preliminary observations from the first 100000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J. 2005;149(2):209–216.
    1. Mangini S, Silveira FS, Silva CP, Grativvol PS, Seguro LF, Ayub SM, et al. Insuficiência cardíaca descompensada na unidade de emergência de hospital especializado em cardiologia. Arq Bras Cardiol. 2008;90(6):400–406.
    1. Montera MW, Pereira SB, Colafranceschi AS, Almeida DR, Tinoco EM, Rocha RM, et al. Summary of the II Brazilian Guideline update on Acute Heart Failure 2009/2011. Arq Bras Cardiol. 2012;98(5):375–383.
    1. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294(15):1944–1956.
    1. Nohria A, Tsang AW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41(10):1797–1804.
    1. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167.
    1. Januzzi JL, Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948–954.
    1. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure. The STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49(16):1733–1739.
    1. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP. TIME-CHF Investigators. BNPguided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–392.
    1. Marcondes-Braga FG, Gutz IG, Batista GL, Saldiva PH, Ayub-Ferreira SM, Issa VS, et al. Exhaled acetone as a new biomaker of heart failure severity. Chest. 2012;142(2):457–466.
    1. Cotter G, Cotter OM, Kaluski E. Hemodynamic monitoring in acute heart failure. Crit Care Med. 2008;36:S40–S43.
    1. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (The ESCAPE Trial) JAMA. 2005;294(13):1625–1633.
    1. Fonarow GC, Adams KF, Jr, Abraham WT, Yancy CW, Boscardin WJ. ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293(5):572–580.
    1. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J. 2012;33(17):2135–2142.
    1. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9(1):13–25.
    1. de Luca L, Fonarow GC, Adams KF, Jr, Mebazaa A, Tavazzi L, Swedberg K, et al. Acute Heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy. Heart Fail Rev. 2007;12(2):97–104.
    1. Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD. Effect of noninvasive positive pressure ventilation on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet. 2006;367(9517):1155–1163.
    1. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng mL, Wynne J. ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications (ADHERE) J Am Coll Cardiol. 2005;46(1):57–64.
    1. Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52(3):200–207.
    1. Elkayam U, Janmohamed M, Habib M, Hatamizadeh P. Vasodilators in the management of acute heart failure. Crit Care Med. 2008;36(1 Suppl):S95–S105.
    1. Petersen JW, Felker M. Inotropes in the management of acute heart failure. Crit Care Med. 2008;36(1 Suppl):S106–S111.
    1. O'Connor CM, Gattis WA, Uretsky BF, Adams KF, Jr, McNulty SE, Grossman SH, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J. 1999;138(1 Pt 1):78–86.
    1. Cuffe MS, Califf RM, Adams KF, Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–1547.
    1. Nieminem MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36(6):1903–1912.
    1. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet. 2002;360(9328):196–202.
    1. Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI. RUSSLAN Study Investigators. Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarction (RUSSLAN) Eur Heart J. 2002;23(18):1422–1432.
    1. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated Herat failure. The SURVIVE randomized trial. JAMA. 2007;297(17):1883–1891.
    1. Van De Borne P, Somers VK. Dopamine and congestive heart failure: pharmacology, clinical use and precautions. Congest Heart Fail. 1999;5(5):216–221.
    1. Gattis WA, O'Connor CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on betablocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91(2):169–174.
    1. Metra M, Torp-Pedersen C, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Dei Cas L, Spark P, Swedberg K, Poole-Wilson PA. COMET investigators. Should betablocker therapy be reduced or withdrawn after episode of decompensaded heart failure? Eur J Heart Failure. 2007;9(9):901–999.
    1. Wang DJ, Gottlieb SS. Diuretics: still the mainstay of treatment. Crit Care Med. 2008;36(1 Suppl):S89–S94.
    1. Chatti R, Fradj NB, Trabelsi W, Kechiche H, Tavares M, Mebazaa A. Algorithm for therapeutic management of acute heart failure syndromes. Heart Fail Rev. 2007;12(2):113–117.
    1. Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure. J Am Coll Cardiol. 2005;45(12):1997–2003.
    1. Issa VS, Bacal F, Mangini S, Carneiro RM, Azevedo CH, Chizzola PR, et al. Solução salina hipertônica para prevenção de insuficiência renal em pacientes com insuficiência cardíaca descompensada e hiponatremia. Arq Bras Cardiol. 2007;89:251–255.
    1. Issa VS, Andrade L, Ayub-Ferreira SM, Bacal F, de Bragança AC, Guimarães GV, et al. Hypertonic saline solution for prevention of renal dysfunction in patients with decompensated heart failure. Int J Cardiol. 2013;167(1):34–40.
    1. Costanzo MR, Guglin ME, Saltzberg MT, Jessup mL, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. UNLOAD. J Am Coll Cardiol. 2007;49(6):675–683. Erratum in: J Am Coll Cardiol. 2007;49(10):1136.
    1. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296–2304.
    1. Miller LW, Guglin M. Patient selection for ventricular assist devices: a moving target. J Am Coll Cardiol. 2012;61(12):1209–1221.
    1. Bacal F, Neto JD, Fiorelli AI, Mejia J, Marcondes-Braga FG, Mangini S, Oliveira Jde L, Jr, de Almeida DR, Azeka E, Dinkhuysen JJ, Moreira Mda C, Neto JM, Bestetti RB, Fernandes JR, Cruz Fd, Ferreira LP, da Costa HM, Pereira AA, Panajotopoulos N, Benvenuti LA, Moura LZ, Vasconcelos GG, Branco JN, Gelape CL, Uchoa RB, Ayub-Ferreira SM, Camargo LF, Colafranceschi AS, Bordignon S, Cipullo R, Horowitz ES, Branco KC, Jatene M, Veiga SL, Marcelino CA, Teixeira GF, Filho, Vila JH, Montera MW. Sociedade Brasileira de Cardiologia. II Brazilian Guidelines for Cardiac Transplantation. Arq Bras Cardiol. 2010;94(1 Suppl):e16–e76. Article in Portuguese.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel